Comparative Pharmacology
Head-to-head clinical analysis: EPHEDRINE SULFATE versus LEVOPHED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPHEDRINE SULFATE versus LEVOPHED.
EPHEDRINE SULFATE vs LEVOPHED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ephedrine sulfate is a sympathomimetic amine that directly stimulates alpha- and beta-adrenergic receptors and indirectly stimulates norepinephrine release from sympathetic neurons, leading to vasoconstriction, bronchodilation, and increased heart rate and contractility.
Norepinephrine acts predominantly on alpha-1 adrenergic receptors to cause vasoconstriction and increase blood pressure. It also has beta-1 adrenergic receptor agonist activity, resulting in positive inotropic effects on the heart.
50 mg orally every 3-4 hours as needed; 25-50 mg intramuscularly or subcutaneously every 3-4 hours; 5-25 mg intravenously slowly every 5-10 minutes as needed, not to exceed 150 mg in 24 hours.
Initial dose: 8-12 mcg/min intravenously, titrate to desired blood pressure; typical maintenance: 2-4 mcg/min IV continuous infusion.
None Documented
None Documented
Terminal elimination half-life 3-6 hours in adults with normal renal function; prolonged in renal impairment or alkaline urine.
The terminal elimination half-life is approximately 2 minutes. The clinical effect is short-lived due to rapid reuptake and metabolism; continuous intravenous infusion is required for sustained effect.
Renal excretion of unchanged drug (60-70%) and minor metabolites; small amount biliary; pH-dependent; acidic urine enhances elimination.
Norepinephrine is primarily metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Less than 5% is excreted unchanged in urine. Metabolites are excreted renally (approximately 80-95% as normetanephrine, vanillylmandelic acid, and other conjugates).
Category C
Category C
Vasopressor
Vasopressor